KLISBio EIC Accelerator Program Project

KLISBio Awarded €2.5 Million EIC Accelerator Program Grant

In 2024 KLISBio has been granted the highly competitive EIC Accelerator Program award by the European Innovation Council and SMEs Executive Agency (EISMEA). This prestigious grant, totaling €2.5 million in non-dilutive funding, is a testament to KLISBio's innovative contributions to the MedTech sector.

The EIC and KLISBio’s Mission: Pioneering Peripheral Nerve Repair Through Innovation

This milestone validates the dedication and innovation that KLISBio brings to the regenerative medicine landscape and the €2.5 million non-dilutive grant will play a pivotal role in transforming Peripheral Nerve Repair through our SILKBridge technology.

EIC-Funded Project Goals

With the €2.5 million grant, KLISBio aims to:

• Scale development of its pioneering SILKBridge® technology for Peripheral Nerve Repair.
• Advance clinical testing and regulatory approvals for its silk-based regenerative solutions.
• Foster partnerships with European medical research institutes and technology developers.
• Enhance its portfolio of innovative solutions in the broader MedTech space.

Latest News

Stay tuned for news and reports on how KLISBio is making strides in regenerative medicine.

Image Gallery

Browse through images related to our project, including lab work, product development, team collaboration, and more.

• Laboratory: Our team working on SILKBridge® technology in the lab.
• Team: Photos of key KLISBio personnel involved in the project.
• Events: Highlights from our participation in industry conferences and workshops.

Join Us in Transforming Regenerative Medicine

KLISBio is always open to collaboration with research institutions, healthcare providers, and industry experts. If you’re interested in learning more or partnering with us, please reach out.